CD274 and classic Hodgkin lymphoma: The combination of IMM01 and tislelizumab (an anti-PD-L1 antibody) had synergistic effects on more patients with classic Hodgkin lymphoma (cHL), with an ORR of 64.3% and a disease control rate (DCR) of 100%.